Sickle Cell Disease: FDA approves first CRISPR gene therapies
Casgevy, one of these treatments, is the first FDA-approved medication to make use of a revolutionary form of genome editing technique
Casgevy, one of these treatments, is the first FDA-approved medication to make use of a revolutionary form of genome editing technique
An approval which can transform the treatment technology for β-thalassemia and sickle-cell disease